Sanofi will also provide funding and scientific inputs into projects of mutual interest, spanning multiple therapeutic areas including autoimmune diseases and inflammatory conditions. The two organizations will create a joint steering committee to fund up to three programs a year. Sanofi will host an annual research forum for researchers from both organizations to further exchange ideas, share knowledge and perspectives on relevant scientific matters, and discuss collaborative research projects.

The first projects that the collaboration will explore are:

• Cytokine crosstalk in type 2 inflammation (effect of Sanofi's investigational molecules on excessive type 2 inflammation)
• Molecular drivers of effector and suppressor T cells in autoimmunity to better understand the specific antigens that may cause type 1 diabetes
• Mechanisms of immune-related adverse events with immune checkpoint inhibitor therapy (focus on pneumonitis and inflammatory arthritis) to explore the role of genomics and pathogenic cell identification